迈向p53稳定药物的合理设计:探究致癌性Y220C突变体的表面
Toward the rational design of p53-stabilizing drugs: probing the surface of the oncogenic Y220C mutant.
作者信息
Basse Nicolas, Kaar Joel L, Settanni Giovanni, Joerger Andreas C, Rutherford Trevor J, Fersht Alan R
机构信息
Medical Research Council Centre for Protein Engineering, Cambridge, UK.
出版信息
Chem Biol. 2010 Jan 29;17(1):46-56. doi: 10.1016/j.chembiol.2009.12.011.
The p53 cancer mutation Y220C induces formation of a cavity on the protein's surface that can accommodate stabilizing small molecules. We combined fragment screening and molecular dynamics to assess the druggability of p53-Y220C and map ligand interaction sites within the mutational cavity. Elucidation of the binding mode of fragment hits by crystallography yielded a clear picture of how a drug might dock in the cavity. Simulations that solvate the protein with isopropanol found additional sites that extend the druggable surface. Moreover, structural observations and simulation revealed the dynamic landscape of the cavity, which improves our understanding of the impact of the mutation on p53 stability. This underpins the importance of considering flexibility of the cavity in screening for optimized ligands. Our findings provide a blueprint for the design of effective drugs that rescue p53-Y220C.
p53癌症突变Y220C会在该蛋白表面诱导形成一个可容纳稳定小分子的腔。我们结合片段筛选和分子动力学来评估p53-Y220C的可药用性,并绘制突变腔内的配体相互作用位点。通过晶体学阐明片段命中物的结合模式,清晰呈现了药物可能如何对接至腔内。用异丙醇使蛋白溶剂化的模拟发现了可扩展可药用表面的其他位点。此外,结构观察和模拟揭示了腔的动态格局,这增进了我们对该突变对p53稳定性影响的理解。这突出了在筛选优化配体时考虑腔的灵活性的重要性。我们的研究结果为设计拯救p53-Y220C的有效药物提供了蓝图。